Tiger Asia Intelligence reiterates a Buy rating on AnPac Bio, Ltd (NASDAQ:ANPC)

Rhea-AI Summary

On Sept. 23, 2020, Tiger Asia Intelligence reiterated a Buy rating on ANPC, highlighting strong growth prospects in cancer screening and immunology post-COVID-19. AnPac's CDA technology offers superior sensitivity and specificity in cancer detection compared to competitors. The company is recognized for its affordable CDA testing, advanced technology, and extensive risk assessment database, which are seen as key advantages in penetrating the Chinese market. AnPac's recovery from COVID-19 is better than expected, with ongoing operations in its San Jose and Philadelphia labs driving performance.

Positive

• Reiterated Buy rating from TAI indicates strong market confidence in ANPC.
• CDA technology shows higher sensitivity and specificity for cancer detection.
• Affordable CDA testing positions AnPac competitively in the market.
• Company recovery from COVID-19 is better than anticipated.
• Ongoing operations in San Jose and Philadelphia labs to enhance business performance.

Negative

• None.

NEW YORK, Sept. 23, 2020 /PRNewswire/ --

The full report can be found here:  AnPac Report

Key Report Highlights:

TAI reiterates a Buy rating on ANPC and sees great opportunity for AnPac in the cancer screening and immunology test markets after the COIVD-19 pandemic. The COVID-19 continues to emerge as a catalyst for future growth and opportunity for newly launched immunology tests. Compared to its competitors, AnPac's CDA technology can detect multiple cancers with relatively higher sensitivity and specificity. AnPac's current valuation is relatively underestimated.

AnPac's relatively low-priced CDA testing, highly accurate technology, and massive risk assessment database are still its competitive advantages to further penetrate the market in China. AnPac continued to work in obtaining the NMPA Class III medical device registration certificate to further penetrate the cancer screening market.

TAI has seen better than expected AnPac's business recovery in China from COVID-19 as well as the operations of its San Jose and Philadelphia labs will continue to drive AnPac's accelerating business performance. 

About Tiger Asia Intelligence:

Tiger Asia Intelligence, a subsidiary of Tiger Market Intelligence, is an independent forward-thinking Research & Market Intelligence company that provides in-depth fundamental equity research on small and mid-cap ADRs. Our unique fundamental research reports, commentary, valuation, and financial models provide investors unique insight into companies generally overlooked by Wall Street.

Website: https://www.tigermarketintelligence.com/

Contact Email: Research@tigerasiaintelligence.com

 

View original content:http://www.prnewswire.com/news-releases/tiger-asia-intelligence-reiterates-a-buy-rating-on-anpac-bio-ltd-nasdaqanpc-301136365.html

SOURCE Tiger Market Intelligence

FAQ

What does Tiger Asia Intelligence report say about ANPC?

The report reiterates a Buy rating for ANPC, emphasizing strong growth potential in cancer screening and immunology.

How does AnPac's CDA technology compare to competitors?

AnPac's CDA technology detects multiple cancers with relatively higher sensitivity and specificity than competitors.

What are the key advantages of AnPac's testing?

Key advantages include relatively low-cost CDA testing, highly accurate technology, and a large risk assessment database.

What is the impact of COVID-19 on AnPac's business?

AnPac's recovery from COVID-19 has been better than expected, improving business performance.

What laboratories is AnPac operating in?

AnPac continues operations in its San Jose and Philadelphia laboratories, contributing to its business growth.